Vivani Medical wants to put semaglutide under your skin. The company is developing an implant version of the drug that currently requires weekly injections. Wegovy users complain about needles. Vivani heard that and thought "what if we made it impossible to stop taking?"
The implant releases the drug continuously. No more forgetting your shot. No more injection site rotation charts that look like a serial killer's planning document. Just a tiny device living rent-free in your body, leaching GLP-1 agonist into your bloodstream while you sleep.
Novo Nordisk sells semaglutide as Wegovy for obesity and Ozempic for diabetes. Both require weekly shots. The market cap is $460 billion because people will pay anything to not feel hungry. Vivani looked at that number and decided they needed a piece. Their angle: make it surgical.
Here's what nobody's asking. What happens when you want to stop? With injections you just skip a week. With an implant you need another procedure. You're not quitting this drug. You're scheduling an extraction appointment and hoping your insurance codes it correctly.
The headline calls this "the latest bet to help patients maintain their weight loss." Maintain is doing incredible work in that sentence. It means you already lost the weight on regular semaglutide. Now you're getting cut open so you don't gain it back. That's not maintenance. That's hostage negotiation with your own appetite.
Retail traders will see "GLP-1 implant" and start Googling Vivani's ticker before learning the company isn't public. They'll pivot to buying more Novo Nordisk shares at all-time highs. Then they'll wonder why their portfolio looks like a diabetes treatment algorithm.
The implant probably works. The drug definitely works. But calling voluntary surgery a solution to forgetting your weekly shot is like buying a house next to the gym because you keep skipping cardio.
Photo by on Unsplash
Leave a Comment